Overview
Aron Skaftason practices in Stockholm, Sweden. Mr. Skaftason is rated as an Advanced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, and Small Lymphocytic Lymphoma (SLL).
His clinical research consists of co-authoring 14 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Chronic B-Cell Leukemia (CBCL).
Locations
Stockholm, AB, Sweden
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Chronic B-Cell Leukemia (CBCL)Mr. Skaftason isAdvanced. Learn about Chronic B-Cell Leukemia (CBCL).
- Chronic Lymphocytic Leukemia (CLL)Mr. Skaftason isAdvanced. Learn about Chronic Lymphocytic Leukemia (CLL).
- Experienced
- Acute Myeloid Leukemia (AML)Mr. Skaftason isExperienced. Learn about Acute Myeloid Leukemia (AML).
- B-Cell LymphomaMr. Skaftason isExperienced. Learn about B-Cell Lymphoma.
- LeukemiaMr. Skaftason isExperienced. Learn about Leukemia.
- Mediastinal TumorMr. Skaftason isExperienced. Learn about Mediastinal Tumor.
- Non-Hodgkin LymphomaMr. Skaftason isExperienced. Learn about Non-Hodgkin Lymphoma.
- Primary Mediastinal B-Cell Lymphoma (PMBCL)Mr. Skaftason isExperienced. Learn about Primary Mediastinal B-Cell Lymphoma (PMBCL).